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Amultitarget PCR was developed for the direct detection of penicillinase-producingNeisseria gonorrhoeae (PPNG). The assay
was validated by testing 342 PPNG isolates and 415 clinical samples. The method is suitable for routine detection of PPNG
strains. Its multitarget approach reduces the potential for false-negative results caused by sequence variations.
Antimicrobial resistance (AMR) in Neisseria gonorrhoeae, thecausative agent of the disease gonorrhea, is a major public
issue and is now recognized by the U.S. Centers for Disease Con-
trol and Prevention (CDC) as one of the top three urgent AMR
threats (1). Action plans to control the impact and spread of N.
gonorrhoeae AMR have been released by the World Health Orga-
nization (WHO) andCDC (2, 3), and prominent among the listed
recommendations is the need to improve AMR surveillance capa-
bilities. Conventional N. gonorrhoeae AMR surveillance is per-
formed by bacterial culture. However, bacterial culture has several
major limitations, including the need for stringent sample han-
dling and transport systems to maintain viable organisms, which
are problems in remote and resource-limited settings. In addition,
nucleic acid amplification tests (NAATs) are increasingly com-
monplace in the diagnosis of gonococcal infections in both remote
and urban settings, which in turn are seeing further reductions in
the use of bacterial culture and widening gaps in AMR data. For
these reasons, there has been an increasing need for the develop-
ment of molecular methods to enhance AMR surveillance activity
(4). We recently described a real-time PCRmethod to detect pen-
icillinase-producing N. gonorrhoeae (PPNG) directly within clin-
ical samples (5). The method acts as an indirect marker for PPNG
by targeting a region of DNA on the gonococcal plasmids carrying
the penicillinase gene but not the penicillinase gene itself. The
original evaluations of this PPNG-PCR showed 100% sensitivity
and 98.7% specificity compared to bacterial culture for detecting
PPNG strains in clinical specimens (5). However, a more recent
evaluation of the assay revealed a variant plasmid type, now called
the Australian plasmid, which was negative by PPNG-PCR (6). In
brief, we tested 342 PPNG isolates from throughout Australia
from the year 2012 and found one isolate that was negative by
PPNG-PCR. DNA sequencing revealed a novel 1,885-bp deletion
(corresponding to nucleotides 502 to 2385 of the Asian plasmid
type, GenBank accession no. U20374), which included the region
targeted by the PPNG-PCR (937 to 1024 bp) and hence accounted
for the false-negative result. Several different gonococcal plasmids
with various different deletions and insertions have now been de-
scribed and named according to the geographical location of their
initial discovery; these include the Asian (7,426 bp), African
(5,599 bp), Rio de Janeiro/Toronto (5,154 bp), Nimes (6,798 bp),
New Zealand (9,309 bp), Johannesburg (4,865 bp), and now the
Australian (3,629 bp) plasmids (6–8).
While our initial data suggest that the Australian plasmid may
be rare in local gonococci, we sought to rectify the PPNG-PCR to
account for this plasmid, particularly given that the PPNG-PCR is
now used as a routine tool to inform gonorrhea treatment guide-
lines in remote parts of Australia where penicillin-based treat-
ments are still used (9). In doing so, we aimed to limit the potential
for false-negative results caused by further unrecognized deletions
or insertions by adopting a multitarget approach. To this effect,
the modified PPNG-PCR method (PPNG-triplex-PCR) is a mul-
tiplex PCRmethod and comprises the original PPNG-PCR oligo-
nucleotides (PPNG target 1, Table 1), a second set of newly de-
signed PPNG oligonucleotides (PPNG target 2, Table 1), and
oligonucleotides targeting the gonococcal opa genes to serve as an
internal control (opa gene target, Table 1). The new PPNG target
2 oligonucleotides target a different region from that of the origi-
nal PPNG-PCR method (corresponding to nucleotides 6160 to
6313 of the Asian plasmid type, GenBank accession no. U20374).
This particular region, which flanks the start of transposon Tn2
(nucleotide 6235; GenBank accession no. U20374), was predicted
to be conserved across all recognized gonococcal plasmid types
based on previous descriptions of these plasmids (6–8) and anal-
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ysis of available sequences from the GenBank database. The opa-
based internal control PCR was included to show that amplifiable
gonococcal DNAwas present when testing nucleic acids extracted
from clinical samples.
The PPNG-triplex-PCR assay consisted of 10.0 l of Quanti-
Tect probe PCRmaster mix (Qiagen, Doncaster, Australia), 0.125
M PPNG target 1 primers (PPNG-t1-F and PPNG-t1-2, Table
1), 0.5 M PPNG target 2 primers (PPNG-t2-F and PPNG-t2-2,
Table 1), 0.25 M opa gene primers (GCopa-F and GCopa-R,
Table 1), 0.2 M each probe (PPNG-t1-probe, PPNG-t2-probe,
andGCopa-Probe, Table 1), and 2.0l of sample extract or isolate
DNA and was made up to 20.0 l using DNase-free water. The
differing primer concentrations were used to limit competition
between the three targets (data not shown). Real-time PCR was
carried out using the Rotor-Gene Q and Rotor-Gene 6000 instru-
ments (Qiagen), with the following cycling parameters: hold at
95°C for 15 min, followed by 45 cycles at 95°C for 15 s and then
60°C for 60 s. Only samples providing cycle threshold (CT) values
of 35 cycles by either of the PPNG-PCR methods were consid-
ered to be true PPNG positives, as previously described (5).
The PPNG-triplex-PCR assay was initially evaluated by retest-
ing the above-mentioned 342 Australian PPNG isolates, which
included representatives of the Asian, African, and Rio de Janeiro/
Toronto plasmids in addition to the Australian plasmid. All iso-
lates provided positive results in both PPNG targets, with the ex-
ception of the isolate harboring the Australian variant, which was
positive by PPNG target 2 and, as expected, was negative by the
PPNG target 1 PCR. To examine clinical performance, the PPNG-
triplex-PCRwas then applied toDNA extracts of 415 clinical sam-
ples (Table 2), providing positive results forN. gonorrhoeae by the
Versant CT/GC DNA NAAT (Siemens Healthcare Diagnostics)
and by supplemental in-house PCR methods. These 415 samples
comprised 94 vaginal (22.7% of samples), 40 urethral (9.6%), 29
cervical (7.0%), 14 throat (3.4%), 11 anal/rectal (2.7%), 2 penile
swabs (0.5%), and 1 eye swab (0.2%) samples, as well as 198 urine
samples (47.7%), 6 joint fluid samples (1.4%), and 20 samples
(4.8%) for which the site was not specified. The extracts were
kindly provided by the RoyalDarwinHospital Laboratory, North-
ern Territory, and comprised all available N. gonorrhoeae NAAT-
positive samples tested by the hospital in the first half of 2014.
Based on the gonorrheal notification data, these were estimated to
comprise approximately 35%of all notified gonorrhea cases in the
Northern Territory during this period. A subset of these samples
(n  193) also had corresponding bacterial culture results. Of
these, 85 were negative by culture (i.e., no gonococci were iso-
lated), 96 were penicillin-lactamase negative, and the remaining
12were identified as PPNGvia phenotypicmethods. The low yield
of culture reflects the challenges of transporting clinical samples
across great distances in the Northern Territory.
The results of the PPNG-triplex-PCR testing for the 415 sam-
ples are summarized in Table 2. In brief, 21 (5.1%) samples were
PPNG positive, and 311 (74.9%) were non-PPNG by the PPNG-
triplex-PCRmethod. A further 83 (20%) sampleswere negative by
both PPNG-PCR methods and the opa internal control PCR and
were considered to be no-call results by the PPNG-triplex-PCR.
Compared to the available culture results, the PPNG-triplex-PCR
assay successfully identified 11 of 12 samples that were PPNG
positive by culture (sensitivity, 91.7%; 95% confidence interval
[CI], 64.6% to 98.5%) and gave complete agreement for the non-
PPNG samples (84/84 samples; specificity, 100%; 95% CI, 95.6%
to 100%). However, the PPNG-triplex-PCR assay missed one
sample that was recorded as PPNG positive by culture. This sam-
ple provided a CT value of 30 cycles in the opa gene PCR, indicat-
ing that amoderate load of amplifiable gonococcal DNAwas pres-
ent. At such a load, wewould have expected the PPNG-PCR assays
to have readily amplified their plasmid targets. The isolate from
this sample was not available for repeat testing. Additional testing
was carried out on the sample using a previously described mul-
tiplex PCR to differentiate -lactamase plasmids of N. gonor-
rhoeae (7), and negative results were again obtained (data not
shown). We therefore do not believe this reflects a false-negative
result by the PPNG-triplex-PCR assay but rather is suggestive of a
sample mixup or data entry error.
Overall, the results show that the PPNG-triplex-PCR is suitable
TABLE 1 Primer and probe information
Primer/probe Sequence (5= to 3=)a Target (positions)b
Reference or
source Supplier
PPNG target 1 (original)
PPNG-t1-F AGCTGTTCGTTTTTTACTACCAATCA PPNG plasmid (937–962) 5 GeneWorks
PPNG-t1-R TGATTTAGTCGTTGAGGTTGAACAA PPNG plasmid (1024–1000) 5 GeneWorks
PPNG-t1-Probe 670-AAGAGTGAATAGTACGCCCACGCTTGA-BHQ2c PPNG plasmid (972–998) 5 Biosearch
Technologies
PPNG target 2 (new)
PPNG-t2-F TTGATTGCCGTAAATGTCCGTA PPNG plasmid (6160–6181) Current study GeneWorks
PPNG-t2-R CTCCACCTTCATCCTCAGCAA PPNG plasmid (6313–6293) Current study GeneWorks
PPNG-t2-Probe FAM-CAGCCCTTCCCGGTCTGTTGAAC-BHQ1 PPNG plasmid (6289–6267) Current study GeneWorks
opa gene target (internal
control target)
GCopa-F TTGAAACACCGCCCGGAA opa genes 10 GeneWorks
GCopa-R TTTCGGCTCCTTATTCGGTTTAA opa genes 10 GeneWorks
GCopa-Probe Yak-CCGATATAATCCGTCCTTCAACATCAG-BHQ1 opa genes 10 Tib Molbiol
a 670, Quasar 670; BHQ, black hole quencher; FAM, 6-carboxyfluorescein; Yak, Yakima yellow;, locked nucleic acid (LNA) bases.
b Positions based on Asian plasmid (GenBank accession no. U20374).
c Sequence is a shortened version of the original PPNG-PCR2 assay (4) with a different fluorophore.
Multitarget PPNG-PCR
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for routine detection of PPNG strains directly in clinical samples
so as to enhance bacterial culture-based surveillance. Moreover,
its multitarget approach limits the potential for sequence varia-
tion to cause false-negative results.
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TABLE 2 Summary of results for the 415 clinical sample extracts
Bacterial culture result
(where available)a
No. of
samples
PPNG-triplex-PCR results (CT range; mean)
Overall resultb PPNG target 1b PPNG target 2b opa gene (internal control)c
PPNG 11 PPNG Positive (24–32; 26) Positive (23–32; 27) Positive (24–44; 30)
1 Non-PPNG Negative Negative Positive (30)
Non-PPNG 84 Non-PPNG Negative Negative Positive (20–40; 29)
12 NC Negative Negative Negative
No growth 2 Non-PPNG Positive (39–42; 40) Negative Positive (32–38; 35)
1 Non-PPNG Negative Positive (39) Positive (38)
62 Non-PPNG Negative Negative Positive (27–45; 33)
20 NC Negative Negative Negative
NP 10 PPNG Positive (23–35; 30)d Positive (23–34; 30) Positive (29–40; 34)
160 Non-PPNG Negative Negative Positive (24–43; 32)
1 Non-PPNG Negative Positive (38) Positive (35)
51 NC Negative Negative Negative
a No growth, bacterial culture was attempted but gonococci were not isolated; NP, not performed, bacterial culture was not attempted on these samples.
b Only samples providing CT value of35 cycles by either of the PPNG-PCR were considered to be true PPNG positives by the PPNG-triplex-PCR. NC, no call; these samples gave
negative results in both PPNG-PCR methods and the opa internal control PCR and therefore did not provide a valid result call by the PPNG-triplex-PCR.
c A CT value cutoff was not used for the opa gene PCR assay, and so all samples providing an amplification curve in the opa assay were considered positive.
d One sample provided a CT value of 35 cycles in target 1 but 34 cycles for target 2 and thus was PPNG positive on the basis of target 2.
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